BELLEVILLE, ON, April 14, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) today announced that its shareholders have voted in favour of the sale of the Company's Animal Health business to Vétoquinol SA.
At a Special Meeting of Shareholders held this morning in Toronto, 39.4% of the issued and outstanding shares were voted, with 97.4% of those voting in favour of the sale transaction.
The transaction is expected to close tomorrow.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a clinical stage Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative therapies for the global human health market. The Company's primary goal is to develop and commercialize products that advance human health and increase shareholder value. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
SOURCE Bioniche Life Sciences Inc.